Article Information
History
- April 24, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Gabriela A. Willis1,*,
- Helen Mayfield1,
- Therese Kearns2,
- Take Naseri3,
- Robert Thomsen3,
- Katherine Gass4,
- Sarah Sheridan5,
- Patricia M. Graves6 and
- Colleen L. Lau1,*
- 1Research School of Population Health, Australian National University, Canberra, Australia
- 2Menzies School of Health Research, Charles Darwin University, Brisbane, Australia
- 3Ministry of Health, Apia, Samoa
- 4Neglected Tropical Diseases Support Center, Task Force for Global Heath, Atlanta, Georgia, United States of America
- 5School of Public Health and Community Medicine, University of New South Wales, Sydney, Australia
- 6College of Public Health, Medical and Veterinary Sciences, James Cook University, Cairns, Queensland, Australia
- ↵*Corresponding authors Email: gabriela.willis{at}health.tas.gov.au (GW), colleen.lau{at}anu.com.au (CL)
Posted April 24, 2020.
An assessment of coverage and adverse events following country-wide triple-therapy mass drug administration for lymphatic filariasis elimination, Samoa 2018
